» Articles » PMID: 34145553

Recent Advances in the Pathology of Prodromal Non-motor Symptoms Olfactory Deficit and Depression in Parkinson's Disease: Clues to Early Diagnosis and Effective Treatment

Overview
Journal Arch Pharm Res
Specialty Pharmacology
Date 2021 Jun 19
PMID 34145553
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disease characterized by movement dysfunction due to selective degeneration of dopaminergic neurons in the substantia nigra pars compacta. Non-motor symptoms of PD (e.g., sensory dysfunction, sleep disturbance, constipation, neuropsychiatric symptoms) precede motor symptoms, appear at all stages, and impact the quality of life, but they frequently go unrecognized and remain untreated. Even when identified, traditional dopamine replacement therapies have little effect. We discuss here the pathology of two PD-associated non-motor symptoms: olfactory dysfunction and depression. Olfactory dysfunction is one of the earliest non-motor symptoms in PD and predates the onset of motor symptoms. It is accompanied by early deposition of Lewy pathology and neurotransmitter alterations. Because of the correlation between olfactory dysfunction and an increased risk of progression to PD, olfactory testing can potentially be a specific diagnostic marker of PD in the prodromal stage. Depression is a prevalent PD-associated symptom and is often associated with reduced quality of life. Although the pathophysiology of depression in PD is unclear, studies suggest a causal relationship with abnormal neurotransmission and abnormal adult neurogenesis. Here, we summarize recent progress in the pathology of the non-motor symptoms of PD, aiming to provide better guidance for its effective management.

Citing Articles

Loganic Acid Alleviates the Olfactory-Brain NLRP3 Inflammasome Activation and Rescues Dopaminergic Neurons in Experimental Models of Parkinson's Disease.

Panda S, Panja P, Singh M, Soni U, Rajdev B, Garg P J Neuroimmune Pharmacol. 2025; 20(1):19.

PMID: 39934492 DOI: 10.1007/s11481-025-10183-9.


Deciphering Depression: Epigenetic Mechanisms and Treatment Strategies.

Aljabali A, Alkaraki A, Gammoh O, Tambuwala M, Mishra V, Mishra Y Biology (Basel). 2024; 13(8).

PMID: 39194576 PMC: 11351889. DOI: 10.3390/biology13080638.


Alpha Synuclein Toxicity and Non-Motor Parkinson's.

Mazzotta G, Conte C Cells. 2024; 13(15.

PMID: 39120295 PMC: 11311369. DOI: 10.3390/cells13151265.


Depression is associated with the nonmotor symptoms of Parkinson's disease: A comparative analysis.

Mayeli M, Shafie M, Shiravi M, Adl Parvar T, Mirsepassi Z, Rahiminejad F Health Sci Rep. 2024; 7(5):e2106.

PMID: 38803654 PMC: 11128496. DOI: 10.1002/hsr2.2106.


Olfactory Dysfunction and Glaucoma.

Iannucci V, Bruscolini A, Iannella G, Visioli G, Alisi L, Salducci M Biomedicines. 2024; 12(5).

PMID: 38790964 PMC: 11117544. DOI: 10.3390/biomedicines12051002.


References
1.
Aarsland D, Bronnick K, Alves G, Tysnes O, Pedersen K, Ehrt U . The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry. 2009; 80(8):928-30. DOI: 10.1136/jnnp.2008.166959. View

2.
Adler C, Beach T, Hentz J, Shill H, Caviness J, Driver-Dunckley E . Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology. 2014; 83(5):406-12. PMC: 4132570. DOI: 10.1212/WNL.0000000000000641. View

3.
Alcalay R, Caccappolo E, Mejia-Santana H, Tang M, Rosado L, Orbe Reilly M . Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology. 2012; 78(18):1434-40. PMC: 3345785. DOI: 10.1212/WNL.0b013e318253d54b. View

4.
Baba T, Takeda A, Kikuchi A, Nishio Y, Hosokai Y, Hirayama K . Association of olfactory dysfunction and brain. Metabolism in Parkinson's disease. Mov Disord. 2011; 26(4):621-8. DOI: 10.1002/mds.23602. View

5.
Bahuleyan B, Singh S . Olfactory memory impairment in neurodegenerative diseases. J Clin Diagn Res. 2012; 6(8):1437-41. PMC: 3471510. DOI: 10.7860/JCDR/2012/3408.2382. View